Ideally, tumors that might cause morbidity and mortality should be treated, preferably early, with proven, convincing, and effective therapy to prevent tumor progression or recurrence, while maintaining a favorable risk-benefit profile for the individual patient. For patients with
colorectal cancer (CRC), this diagnostic, prognostic, and therapeutic precision is currently impossible. Despite significant improvements in diagnostic procedures, a sizable number of patients with CRC have liver metastases either at presentation or will subsequently develop it. And in many parts of the world, most cancer-related deaths are still due to metastases that are resistant to conventional therapy. Metastases to the liver occur in more than 50% of patients with CRC and represent the major determinant of outcome following curative treatment of the primary tumor. Liver resection offers the best chance of cure for metastases confined to the liver. However, due to a paucity of randomized controlled trials, its timing is controversial and a hotly debated topic. This article reviews some of the main controversies
surrounding the surgical management of colorectal cancer liver metastases (CRLM).
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:13165 |
| Date | January 2015 |
| Creators | Kassahun, Woubet T. |
| Contributors | Universität Leipzig |
| Publisher | BioMed Central |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Source | World Journal of Surgical Oncology (2015) 13:61 DOI 10.1186/s12957-014-0420-6 |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0023 seconds